Delivery Order SPE2DB24D2106-SPE2DB25FAUYP

Award Date 4/8/25
Potential Completion Date 4/9/25
Potential Value $1.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,427.36 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The delivery order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued at $499,999,999, which allows the DLA to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,796.81, is for the supply of Quillivant XR 25 mg/5 ml suspension, a prescription medication. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the...
This federal contract award issued by the Defense Logistics Agency (DLA) is a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,537.17 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized prescription medication. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,366.07 contract is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a performance period ending on May 20, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the agency to issue delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,605.38 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a prescription medication. The award is not associated with any set-aside designations. DMS Pharmaceutical Group holds a significant $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The $5,393.20 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) under the SPE2DB24 indefinite delivery contract, which has a ceiling value of up to $499,999,999 and runs through December 31, 2025. This single-award IDC allows the DLA to issue delivery orders for a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $1,314.20, is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) and has a period of performance through May 13, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the agency to issue...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,451.98 firm fixed-price delivery order is for the supply of 120 ml bottles of the prescription medication Quillivant XR (25 mg/5 ml suspension). The award is not associated with a set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,440.48 contract is for the delivery of Quillivant XR 25 mg/5 ml suspension in a 150 ml bottle. The contract has an ultimate completion date of March 3, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract...
This is a delivery order contract (SPE2DB20D6037|SPE2DB25FTUE9) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,051.36 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
  • SPE2DB24D2106
    Indefinite Delivery Contract
  • SPE2DB24D2106-SPE2DB25FAUYP
    Delivery Order

This is a $1,903.48 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized medication, to support the medical supply needs of military healthcare facilities.

The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.

Generated 7/8/25, 2:23 PM